Immobilized Metal Affinity Chromatography Resin
Bio-Rad Laboratories’ Nuvia IMAC Resin, an immobilized metal affinity chromatography resin, is optimized for use from laboratory-scale through pilot studies to process-scale manufacturing.
Metal affinity chromatography was developed for the purification of native proteins with an intrinsic affinity to metal ions. Immobilized metal affinity chromatography (IMAC) has a broad range of applications, although its primary application is for the purification of histidine-tagged recombinant proteins that can bind nickel, cobalt, and copper ions. IMAC is also used for isolating phosphorylated proteins and zinc finger or copper-binding proteins.
Nuvia IMAC Resin uses a polymeric bead with a narrow particle size range (mean particle size is 50 micrometer), which enables the particles to maintain superior flow properties at any scale. The resin particle size and porosity allow constant and high binding capacity, even at high flow rates, while maintaining the low backpressure required for process-scale manufacturing. Additional benefits of Nuvia IMAC include: high productivity; broad chemical stability; and low, nonspecific binding that increases the purity of the final product because fewer non-target proteins bind to the hydrophilic polymer resin.
Along with the Nuvia IMAC, Bio-Rad offers a wide range of process resins, delivering greater flexibility for lead discovery and process development. When used together with the NGC Chromatography System and accompanying ChromLab Software, these resins simplify and expedite multicolumn purifications into a single automated step.
Source: Bio-Rad
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
